Document:

EX-10.28

 Exhibit 10.28 
 BOD 
 DIRECTOR STOCK OPTION GRANT AGREEMENT 

THIS AGREEMENT, made as of this XXth day of Month Year between WP Prism Inc. (the “Company”) and Director’s Name,
(the “Participant”). 
 WHEREAS, the Company has adopted and maintains the WP Prism Inc. Management Stock
Option Plan (the “Plan”) to promote the interests of the Company and its Affiliates and shareholders by providing the Company’s key employees, directors and others with an appropriate incentive to encourage them to continue in
the employ of and provide services for the Company or its Affiliates and to improve the growth and profitability of the Company; 
 WHEREAS, the Plan provides for the Grant to Participants of Options to purchase shares of Common Stock of the Company. 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants hereinafter set forth, the parties hereto hereby agree as follows: 

 

	1.	Grant of Options. Pursuant to, and subject to, the terms and conditions set forth herein and in the Plan, the Company hereby grants to the Participant an option (the
“Option”) with respect to XXXX shares of Common Stock of the Company. 100% of the Option will be a Time-Based Option. 

  

	2.	Grant Date. The Grant Date of the Option hereby granted shall be Month Date, Year . 

 

	3.	Incorporation of Plan. All terms, conditions and restrictions of the Plan are incorporated herein and made part hereof as if stated herein. If there is any conflict
between the terms and conditions of the Plan and this Agreement, the terms and conditions of this Plan, as interpreted by the Committee, shall govern. All capitalized terms used and not defined herein shall have the meaning given to such terms in
the Plan. 

  

	 	a.	 Cause. Notwithstanding the foregoing, for purposes of the Plan and this Agreement, “Cause,” when used in connection with the removal
of a Participant from the Board, means (i) a failure of the Participant to substantially perform his or her duties (other than as a result of physical or mental illness or injury), including, without limitation, failure to attend all Board
meetings in person unless the Participant’s absence is approved in advance by the Company, that has continued after BOL or the Company has provided written notice of such failure and the Director Shareholder has not cured such failure within 30
days of the date of such written notice; (ii) the Participant’s willful misconduct or gross negligence in the performance of his or her duties for BOL or the Company; (iii) a willful or grossly negligent breach by the Participant of
the Participant’s fiduciary duty or duty of loyalty to BOL, the Company or their respective Affiliates; (iv) the commission by the Participant of any felony or other serious crime involving moral turpitude; (v) a material breach of
the Participant’s obligations under any agreement 

	 	
entered into between the Participant and the Company or any of its Affiliates, which, if such breach is reasonably susceptible to cure, has continued after BOL or the Company has provided written
notice of such breach and the Participant has not cured such failure within 30 days of the date of such written notice; or (vii) a material breach of BOL or the Company’s written policies or procedures that have been communicated to the
Participant and that causes material harm to BOL, the Company or their respective Affiliates or their respective business reputations. 

  

	4.	Vesting. Twenty percent (20%) of the Option shall vest and become exercisable on each of the first five anniversaries of the Grant Date, until 100% of the Option
is fully vested and exercisable, subject in all cases to the Participant’s continued service on the Board through the applicable Vesting Date. 

  

	5.	Exercise Price. The exercise price of each share of Common Stock underlying the Option hereby granted is $XX.XX. 

 

	6.	Construction of Agreement. Any provision of this Agreement (or portion thereof) which is deemed invalid, illegal or unenforceable in any jurisdiction shall, as to that
jurisdiction and subject to this section, be ineffective to the extent of such invalidity, illegality or unenforceability, without affecting in any way the remaining provisions thereof in such jurisdiction or rendering that or any other provisions
of this Agreement invalid, illegal, or unenforceable in any other jurisdiction. If any covenant should be deemed invalid, illegal or unenforceable because its scope is considered excessive, such covenant shall be modified so that the scope of the
covenant is reduced only to the minimum extent necessary to render the modified covenant valid, legal and enforceable. No waiver of any provision or violation of this Agreement by the Company shall be implied by the Company’s forbearance or
failure to take action. This Agreement is intended to comply with Section 409A of the Code and any guidance issued thereunder and shall be interpreted, operated and administered accordingly. 

 

	7.	Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party hereto upon any breach or default of any party under this
Agreement, shall impair any such right, power or remedy of such party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring nor shall any
waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under
this Agreement, or any waiver on the part of any party or any provisions or conditions of this Agreement, shall be in writing and shall be effective only to the extent specifically set forth in such writing. 

 

	8.	 Limitation on Transfer. The Option shall be exercisable only by the Participant or the Participant’s Permitted Transferee(s), as determined in
accordance with the terms of the Plan (including without limitation the requirement that the Participant obtain the prior written approval by the Committee of any proposed Transfer to a Permitted Transferee during the lifetime of the Participant).
Each Permitted Transferee shall be subject to all the restrictions, obligations, and responsibilities as apply to the Participant under the Plan and this Stock Option Grant Agreement and shall be entitled to all the rights of the Participant under
the 

  
 2 

	 	
Plan, provided that in respect of any Permitted Transferee which is a trust or custodianship, the Option shall become exercisable and/or expire based on the Employment and termination of
Employment of the Participant. All shares of Common Stock of the Company obtained pursuant to the Option granted herein shall not be transferred except as provided in the Plan and, where applicable, the Shareholders’ Agreement.

  

	9.	Non-Disclosure of Confidential Information; Non-Solicitation. In consideration the Grant, by the Company (which, for purposes of this Section 9, shall include all
of the Company’s subsidiaries and all affiliated companies and joint ventures connected by ownership to the Company at any time (but not any other portfolio companies of the Sponsor)), of an Option pursuant to this Agreement, Participant makes
the following covenants: 

  

	 	(a)	Non-disclosure of Confidential Information and Trade Secrets. During Participant’s service on the Board and thereafter, except in the good faith performance
of Participant’s duties hereunder or where required by law, statute, regulation or rule of any governmental body or agency, or pursuant to a subpoena or court order, Participant shall not, directly or indirectly, for Participant’s own
account or for the account of any other person, firm or entity, use or disclose any Confidential Information or proprietary Trade Secrets of the Company to any third person unless such Confidential Information or Trade Secret has been previously
disclosed to the public or is in the public domain (other than by reason of Participant’s breach of this paragraph). 

  

	 	(b)	Non-solicitation of Company Customers and Suppliers. During the Participant’s service on the Board and for the twelve month period following the date on
which the Participant ceases to serve on the Board for any reason (the “Restricted Period”), Participant shall not, directly or indirectly, on behalf of Participant or of anyone other than the Company, solicit or hire or attempt to
solicit or hire (or assist any third party in soliciting or hiring or attempting to solicit or hire) any of the Company’s then-current and actively-sought potential customers (“Customers”) or suppliers of inventory
(“Suppliers”) in connection with any business activity that is operated by a Competitor (as defined below) of the Company. 

  

	 	(c)	Non-solicitation of Company Employees. During the Restricted Period, Participant shall not, without the prior written consent of the Board, directly or
indirectly, on behalf of Participant or any third party, solicit or hire or recruit or, other than in the good faith performance of Participant’s duties, induce or encourage (or assist any third party in hiring, soliciting, recruiting, inducing
or encouraging) any employees of the Company or any individuals who were employees within the six-month period immediately prior thereto to terminate or otherwise alter his or her employment with the Company. Notwithstanding the foregoing, the
restrictions contained in this Section 9(c) shall not apply to (i) general solicitations that are not specifically directed to employees of the Company or (ii) serving as a reference at the request of an employee.

  

	 	(d)	 Definition of Competitor. For purposes of this Section 9, a Competitor of the Company shall mean (i) any unit, division, line of
business, parent, subsidiary or subsidiary of the parent of any of Alcon, Advanced Medical Optics, Inc., Allergan, Inc., Johnson & Johnson (provided that, with respect to Johnson & Johnson, this provision shall be limited to
Johnson & Johnson businesses that are primarily engaged 

  
 3 

	 	
in the provision of ophthamological products, including, without limitation, the Vistakon Division), CIBA Vision, Carl Zeiss Meditec, Inc., STAAR Surgical Company, Cooper Companies, Santen
Pharmaceutical Co., Ltd., and ISTA Pharmaceuticals; or (ii) any individual or entity that within two years after your termination could reasonably be expected to generate more than $50 Million in annualized gross revenue from any activity that
competes, or combination of activities that competes, with any business of the Company; provided, that a Competitor of the Company under this clause (ii) shall not include any individual or entity or portion of an entity where
(A) Participant has actual supervisory duties and authority over one or more businesses and (B) less than 20% of the annualized gross revenue of such businesses over which Participant has actual supervisory duties and authority arise from
any activity or combination of activities that competes with any business of the Company. Notwithstanding the foregoing, in the event any of the above-named entities in clause (i) of this Section 9(d) no longer engages in a line of
business that competes with any business of the Company, such entity shall no longer be deemed a Competitor of the Company for purposes of this Section 9 

 

	 	(e)	Enforceability of Covenants. Participant acknowledges the reasonableness of the term and scope of the covenants set forth in this Section 9, and Participant
agrees that Participant will not, in any action, suit or other proceeding, deny the reasonableness of, or assert the unreasonableness of, the premises, consideration or scope of the covenants set forth herein and Participant hereby waives any such
defense. Participant further acknowledges that complying with the provisions contained in this Agreement will not preclude Participant from engaging in a lawful profession, trade or business, or from becoming gainfully employed. Participant agrees
that Participant’s covenants under this Section 9 are separate and distinct obligations under this Agreement, and the failure or alleged failure of the Company or the Board to perform obligations under any other provisions of this
Agreement shall not constitute a defense to the enforceability of Participant’s covenants and obligations under this Section 9. Participant agrees that any breach of any covenant under this Section 9 will result in irreparable damage
and injury to the Company and that the Company will be entitled to injunctive relief in any court of competent jurisdiction without the necessity of posting any bond. 

 

	10.	Integration. This Agreement, and the other documents referred to herein or delivered pursuant hereto which form a part hereof contain the entire understanding of the
parties with respect to its subject matter. There are no restrictions, agreements, promises, representations, warranties, covenants or undertakings with respect to the subject matter hereof other than those expressly set forth herein and in the
Plan. This Agreement, including without limitation the Plan, supersedes all prior agreements and understandings between the parties with respect to its subject matter, except to the extent of any conflict between the provisions hereof and an
employment agreement effective on the date hereof. 

  

	11.	Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same
instrument. 

  

	12.	Governing Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware without regard to the provisions
governing conflict of laws. 

  
 4 

	13.	Participant Acknowledgment. The Participant hereby acknowledges receipt of a copy of the Plan. The Participant hereby acknowledges that all decisions, determinations
and interpretations of the Committee in respect of the Plan, this Agreement and the Option shall be final and conclusive. The Participant further acknowledges that, prior to a QPO, no exercise of the Option or any portion thereof shall be effective
unless and until the Participant has executed the Shareholders’ Agreement and the Participant hereby agrees to be bound thereby. 

 *        *        *        *        *

  
 5 

 IN WITNESS WHEREOF, the Company has caused this Agreement to be duly executed by its duly
authorized officer and said Participant has hereunto signed this Agreement on his own behalf, thereby representing that he has carefully read and understands this Agreement, the Plan and the Shareholders’ Agreement as of the day and year first
written above. 
  

	
	WP Prism Inc.
	
	  

	By:
	Title:
	
	  

	Director’s Name

  
 6EX-10.29

 Exhibit 10.29 
 TRANSFORMATION GRANT AGREEMENT 
 THIS TRANSFORMATION GRANT AGREEMENT (this
“Agreement”) is made as of the 14th day of August 2012 between WP Prism Inc. (the “Company”) and Brenton L. Saunders (the “Grantee”). 

WHEREAS, the Board of Directors of the Company (the “Board”) has approved the grant of a special equity award in the
form of restricted shares of the Company’s common stock, par value $.001 per share (the “Common Stock”). 

NOW, THEREFORE, in consideration of the premises and the mutual covenants hereinafter set forth, the parties hereto hereby agree as
follows: 
 1. Grant of Restricted Stock. Pursuant to, and subject to, the terms and conditions set forth in this
Agreement and the Employee Shareholders Agreement between the Company and the Grantee, dated as of March 15, 2010 (the “Shareholders’ Agreement”), the Company hereby grants to the Grantee 315,000 restricted shares of Common
Stock (the “Restricted Stock”). Any capitalized term used but not defined herein shall have the meaning ascribed to such term in the Shareholders’ Agreement. 

2. Grant Date. The grant date of the Restricted Stock hereby granted is August 14, 2012 (the “Grant Date”).

 3. Rights of the Grantee. The Grantee’s rights with respect to all the shares of Restricted Stock shall not vest
and will remain forfeitable at all times prior to the Vesting Date (as defined below). Except as otherwise provided in this Agreement, the Grantee shall be entitled, at all times on and after the Grant Date, to exercise all rights of a shareholder
with respect to the shares of Restricted Stock, including the right to vote the shares of Restricted Stock, if any. Prior to the Vesting Date, the Grantee shall not be entitled to transfer, sell, pledge, hypothecate or assign any portion of the
shares of Restricted Stock, except that the Grantee may transfer any or all of the Restricted Stock to his beneficiaries or estate upon his death (by will, by the laws of descent and distribution or otherwise). 

4. Vesting. Subject in each case to the FMV Vesting Condition (as defined below), the shares of Restricted Stock shall vest and no
longer be forfeitable as follows: 
 4.1 The Restricted Stock shall vest upon the earliest to occur of (A) the second
anniversary of the Grant Date, (B) a Change of Control and (C) the date on which the Grantee’s Employment terminates as a result of (x) a termination by the Company without Cause (as defined in the Grantee’s Stock Option Grant
Agreement with the Company dated as of March 15, 2010) or (y) the Grantee’s death or Disability (such date, the “Vesting Date”). In the event that the Vesting Date occurs as a result of clause (C) above, the portion of the
Restricted Stock that shall vest shall be equal to a fraction, the numerator of which is the number of whole months that have elapsed between the Grant Date and the Vesting Date and the denominator of which is 24, and any remaining portion of the
Restricted Stock shall be forfeited immediately. In all other cases, subject to the FMV Vesting Condition, the Restricted Stock shall vest in full upon the Vesting Date. 

 4.2 Notwithstanding the foregoing, the Restricted Stock shall be immediately forfeited in
full if (A) the Grantee’s Employment terminates at any time (including following the Vesting Date) for any reason other than as described in clause 4.1(C) above, (B) the Grantee breaches any restrictive covenant to which he is subject at any
time (including following the Vesting Date) or (C) as of the Vesting Date, the FMV Vesting Condition is not satisfied. For purposes of this Agreement, the “FMV Vesting Condition” shall mean that the Fair Value of a share of the
Common Stock is at least $38.50. 
 4.3 Delivery of Shares. The Company shall issue certificates, or make a “book
entry” on the books and records of the Company, representing the shares of Restricted Stock issued and held by the Grantee; provided that prior to the Vesting Date, the shares of Restricted Stock shall be held by the Company in escrow
(together with any stock transfer powers which the Company may request of the Grantee) and shall remain in the custody of the Company until (a) their delivery (in either certificate or “book entry” form) to the Grantee upon the Vesting
Date; or (b) their forfeiture as set forth above. The shares of Restricted Stock shall at all times be subject to the terms and conditions of the Shareholders’ Agreement, as modified herein. 

5. Non-solicitation, Non-recruitment and Non-competition. In consideration of the Grantee’s employment with the Company
(which, for purposes of this Section 5, shall include all of the Company’s subsidiaries and all affiliated companies and joint ventures connected by ownership to the Company at any time (but not any other portfolio companies of the
Sponsor)) and the grant of the Restricted Stock pursuant to this Agreement, the Grantee makes the following covenants described in this Section 5: 
 5.1 Non-solicitation of Company Customers and Suppliers. During the Grantee’s Employment and for the twelve month period following the termination of such Employment for any reason (the
“Restricted Period”), the Grantee shall not, directly or indirectly, on behalf of himself or of anyone other than the Company, solicit or hire or attempt to solicit or hire (or assist any third party in soliciting or hiring or
attempting to solicit or hire) any of the Company’s then-current and actively-sought potential customers (“Customers”) or suppliers of inventory (“Suppliers”) in connection with any business activity that is
operated by a Competitor (as defined below) of the Company. 
 5.2 Non-solicitation of Company Employees. During the
Restricted Period, the Grantee shall not, without the prior written consent of the Board, directly or indirectly, on behalf of himself or any third party, solicit or hire or recruit or, other than in the good faith performance of the Grantee’s
duties, induce or encourage (or assist any third party in hiring, soliciting, recruiting, inducing or encouraging) any employees of the Company or any individuals who were employees within the six-month period immediately prior thereto to terminate
or otherwise alter his or her employment with the Company. Notwithstanding the foregoing, the restrictions contained in this Section 5.2 shall not apply to (i) general solicitations that are not specifically directed to employees of the
Company or (ii) serving as a reference at the request of an employee. 

 5.3 Non-competition with the Company. During the Restricted Period, the Grantee shall
not become an employee, director, or independent contractor of, or consultant to, or perform any services for, any Competitor of the Company. For purposes of this Section 5, a Competitor of the Company shall mean (i) any unit, division,
line of business, parent, subsidiary or subsidiary of the parent of any of Novartis, Abbott Medical Optics, Inc., Allergan, Inc., Johnson & Johnson, Carl Zeiss Meditec, Inc., STAAR Surgical Company, Cooper Companies and Santen
Pharmaceutical Co., Ltd. (provided that, with respect to Johnson & Johnson and Novartis, this provision shall be limited to Johnson & Johnson and Novartis businesses that are primarily engaged in the provision of ophthamological
products, including, without limitation, the Vistakon division of Johnson & Johnson and the Alcon and CIBA Vision divisions of Novartis); or (ii) any individual or entity that within two years after your termination could reasonably be
expected to generate more than $50 Million in annualized gross revenue from any activity that competes, or combination of activities that competes, with any business of the Company; provided, that a Competitor of the Company under this clause
(ii) shall not include any individual or entity or portion of an entity where (A) the Grantee has actual supervisory duties and authority over one or more businesses and (B) less than 20% of the annualized gross revenue of such
businesses over which the Grantee has actual supervisory duties and authority arise from any activity or combination of activities that competes with any business of the Company. Notwithstanding the foregoing, in the event any of the above-named
entities in clause (i) of this Section 5.3 no longer engages in a line of business that competes with any business of the Company, such entity shall no longer be deemed a Competitor of the Company for purposes of this Section 5.

 5.4 Non-disclosure of Confidential Information and Trade Secrets. During the term of the Grantee’s Employment and
thereafter, except in the good faith performance of the Grantee’s duties hereunder or where required by law, statute, regulation or rule of any governmental body or agency, or pursuant to a subpoena or court order, the Grantee shall not,
directly or indirectly, for his own account or for the account of any other person, firm or entity, use or disclose any Confidential Information (as defined in the Company’s Management Stock Option Plan) or proprietary Trade Secrets (as defined
in the Company’s Management Stock Option Plan) of the Company to any third person unless such Confidential Information or Trade Secret has been previously disclosed to the public or is in the public domain (other than by reason of the
Grantee’s breach of this paragraph). 
 5.5 Enforceability of Covenants. The Grantee acknowledges that the Company
has a present and future expectation of business from and with the Customers and Suppliers. The Grantee acknowledges the reasonableness of the term, geographical territory, and scope of the covenants set forth in this Section 5, and the Grantee
agrees that he will not, in any action, suit or other proceeding, deny the reasonableness of, or assert the unreasonableness of, the premises, consideration or scope of the covenants set forth herein and the Grantee hereby waives any such defense.
The Grantee further acknowledges that complying with the provisions contained in this Agreement will not preclude the Grantee from engaging in a lawful profession, trade or business, or from becoming gainfully employed. The Grantee agrees that his
covenants under this Section 5 are separate and distinct obligations under this Agreement, and the failure or alleged failure of the Company or the Board to perform obligations under any other provisions of this Agreement shall not constitute a
defense to the enforceability of the Grantee’s covenants and obligations under this Section 5. The Grantee agrees that any breach of any covenant under this 

 
Section 5 will result in irreparable damage and injury to the Company and that the Company will be entitled to injunctive relief in any court of competent jurisdiction without the necessity
of posting any bond. 
 6. Call Rights: No Put Rights; Tag Along Rights: Piggyback Registration Rights. Notwithstanding
anything to the contrary in the Shareholders’ Agreement: 
 6.1 Call Rights. In the event that, following the
Vesting Date, the Grantee’s Employment terminates for any reason other than a termination by the Company for Cause, the Company shall have the call right described in Section 3(b)(i) of the Shareholders’ Agreement with respect to the
Restricted Stock. 
 6.2 No Put Rights. The Grantee shall not have any put right with respect to the Restricted Stock
(either before or after the Vesting Date). 
 6.3 Tag Along Rights. The Tag Along Rights described in Section 4(b)
of the Shareholders’ Agreement shall only apply to the Restricted Stock following the Vesting Date. 
 6.4 Piggyback
Registration Rights. The Piggyback Registration Rights described in Section 5(b) of the Shareholders’ Agreement shall only apply to the Restricted Stock following the Vesting Date. 

7. Adjustment Upon Changes in Common Stock. 
 7.1 Increase or Decrease in Issued Shares Without Consideration. Subject to any required action by the stockholders of the Company, in the event of any increase or decrease in the number of issued
shares of Common Stock resulting from a subdivision or consolidation of shares of Common Stock or the payment of a stock dividend (but only on the shares of Common Stock), or any other increase or decrease in the number of such shares effected
without receipt of consideration by the Company, the Board shall make such adjustments with respect to the number of shares of Restricted Stock, as the Board may, in its good faith discretion, consider appropriate to prevent the enlargement or
dilution of rights. 
 7.2 Certain Mergers. Subject to any required action by the stockholders of the Company, in the
event that the Company shall be the surviving corporation in any merger or consolidation (except a merger or consolidation as a result of which the holders of shares of Common Stock receive securities of another corporation), the shares of
Restricted Stock outstanding on the date of such merger or consolidation shall pertain to and apply to (on the same terms and conditions as apply to the shares of Restricted Stock, unless otherwise determined by the Board) the securities that a
holder of the number of shares of Common Stock underlying the shares of Restricted Stock would have received in such merger or consolidation (it being understood that if, in connection with such transaction, the stockholders of the Company retain
their shares of Common Stock and are not entitled to any additional or other consideration, the shares of Restricted Stock shall not be affected by such transaction). 
 7.3 Certain Other Transactions. In the event of (i) a dissolution or liquidation of the Company, (ii) a sale of all or substantially all of the Company’s assets, (iii) a merger
or consolidation involving the Company in which the Company is not the surviving corporation or 

 
(iv) a merger or consolidation involving the Company in which the Company is the surviving corporation but the holders of shares of Common Stock receive securities of another corporation and/or
other property, including cash, the Board shall, in its sole discretion, (a) have the power to provide for the exchange of the shares of Restricted Stock outstanding immediately prior to such event (whether or not then exercisable) for shares
of Restricted Stock on some or all of the property for which the Common Stock is exchanged and, incident thereto, make such equitable adjustment to the shares of Restricted Stock and this Agreement, as determined by the Board; and/or, (b) if
appropriate, cancel, effective immediately prior to such event, the shares of Restricted Stock (whether or not vested) and in full consideration of such cancellation pay to the Grantee an amount in cash, with respect to each share of Restricted
Stock, equal to the value, as determined by the Board in its good faith discretion, of securities and/or property (including cash) received by such holders of shares of Common Stock as a result of such event, as the Board may consider appropriate to
prevent dilution or enlargement of rights. 
 7.4 Other Changes. In the event of any change in the capitalization of the
Company or a corporate change other than those specifically referred to in Sections 7.1 through 7.4 hereof, or in the event a Public Market exists for the securities of any Affiliate of the Company, the Board shall, in its good faith discretion,
make such adjustments to the shares of Restricted Stock or the terms of this Agreement as the Board may consider appropriate to prevent dilution or enlargement of rights. 
 7.5 No Other Rights. Except as expressly provided in this Agreement, the Grantee shall not have any rights by reason of (i) any subdivision or consolidation of shares of Common Stock or shares
of stock of any class, (ii) the payment of any dividend, or any increase or decrease in the number of shares of Common Stock, or (iii) any dissolution, liquidation, merger or consolidation of the Company or any other corporation. No
issuance by the Company of shares of Common Stock or shares of stock of any class, or securities convertible into shares of Common Stock or shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect
to, the shares of Restricted Stock. 
 7.6 Adjustments to Common Stock. As used herein, references to the terms
“Common Stock” or “shares of Restricted Stock” shall also be references to securities of any kind whatsoever received in exchange for such shares of Common Stock or shares of Restricted Stock. 

8. Disclaimer of Rights. No provision in this Agreement shall be construed to confer upon any individual the right to remain in
the employ or service of the Company or any Affiliate of the Company, or to interfere in any way with any contractual or other right or authority of the Company or any Affiliate of the Company either to increase or decrease the compensation or other
payments to any individual at any time, or to terminate any employment between any individual and the Company or an Affiliate of the Company. 
 9. Withholding of Taxes. To satisfy any federal, state, or local taxes or withholding of any kind required by law to be withheld with respect to any vesting, payments, distributions and property
transferred under this Agreement, the Company shall have the right to (i) deduct an amount from payments of any kind otherwise due to the Grantee; (ii) deduct a number of shares of Common Stock that would otherwise be delivered to or held
by Grantee; or (iii) require the Grantee to deliver to the Company an amount in cash, in any case as determined by the Company in its sole discretion, sufficient to satisfy any such obligation. 

 10. Severability. If any provision of this Agreement shall be determined to be
illegal or unenforceable by any court of law in any jurisdiction, the remaining provisions thereof and hereof shall be severable and enforceable in accordance with their terms, and all provisions shall remain enforceable in any other jurisdiction.

 11. Representations. The Grantee hereby represents and warrants to the Company and
its Affiliates that: (a) the Grantee is aware that this Agreement and the Shareholders’ Agreement provide significant restrictions on the ability of the Grantee to sell, transfer, assign, mortgage, hypothecate, or otherwise encumber the
shares of Restricted Stock; (b) the Grantee has duly executed and delivered this Agreement and the Shareholders’ Agreement; and (c) the Grantee’s authorization, execution, delivery, and performance of this Agreement and the
Shareholders’ Agreement does not conflict with any other agreement or arrangement to which the Grantee is a party or by which it is bound. 
 12. Integration. This Agreement, and the other documents referred to herein or delivered pursuant hereto, contain the entire understanding of the parties with respect to its subject matter and
there are no restrictions, agreements, promises, representations, warranties, covenants or undertakings with respect to the subject matter hereof other than those expressly set forth in such documents. This Agreement and the Shareholders’
Agreement supersede all prior agreements and understandings between the parties with respect to its subject matter. 
 13.
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument. 

14. Governing Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of
Delaware without regard to the provisions thereof governing conflict of laws. 
 15. Binding Effect. This Agreement shall
be binding upon and inure to the benefit of the parties hereto and their respective heirs, executors, administrators, successors, and assigns. 
 16. Notice. All notices or other communications which may be or are required to be given by any party to any other party pursuant to this Agreement shall be delivered in accordance with the
requirements of the Shareholders’ Agreement. 
 17. Delays or Omissions. No delay or omission to exercise any right,
power or remedy accruing to any party hereto upon any breach or default of any party under this Agreement, shall impair any such right, power or remedy of such party nor shall it be construed to be a waiver of any such breach or default, or an
acquiescence therein, or of or in any similar breach or default thereafter occurring nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit,
consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party or any provisions or conditions of this Agreement, shall be in writing and shall be effective
only to the extent specifically set forth in such writing. 

							
	 Oct 01 2012 12:06PM HP Fax 9086040086
	  	 	page 2	  	  	

 IN WITNESS WHEREOF, the Company has caused this Agreement to be duly executed by its duly authorized officer and the
Grantee has hereunto signed this Agreement on his/her own behalf, thereby representing that he/she has carefully read and understands this Agreement as of the day and year first written above. 

 

			
	WP PRISM INC.
	
	 /s/ Sean D. Carney

	By:	 	Sean D. Carney
	Title:	 	Director, and Managing Director, Warburg Pincus LLC
	
	BRENTON L. SAUNDERS
	
	 /s/ Brenton L. Saunders

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}]]